Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
[Preprint]. 2023 May 10:rs.3.rs-2787493.
doi: 10.21203/rs.3.rs-2787493/v1.

Validation Study on Risk-Reduction Activities after Exposure to a Personalized Breast Cancer Risk-Assessment Education Tool in High-Risk Women in the WISDOM Study

Tianyi Wang  1   2 , Mandy Che  1   3 , Yash S Huilgol  4 , Holly Keane  5 , Deborah Goodman  6 , Rashna Soonavala  1 , Elissa Ozanne  7 , Yiwey Shieh  8 , Jeffrey K Belkora  4 , Allison Stover Fiscalini  1 ; Athena Breast Health Network Investigators and Advocate Partners; Laura J Esserman  1
Affiliations

Validation Study on Risk-Reduction Activities after Exposure to a Personalized Breast Cancer Risk-Assessment Education Tool in High-Risk Women in the WISDOM Study

Tianyi Wang et al. Res Sq. .

Update in

Abstract

We performed a 318-participant validation study of an individualized risk assessment tool in women identified as having high- or highest-risk of breast cancer in the personalized arm of the Women Informed to Screen Depending on Measures of risk (WISDOM) trial. Per protocol, these women were educated about their risk and risk reducing options using the Breast Health Decisions (BHD) tool, which uses patient-friendly visuals and 8th grade reading level language to convey risk and prevention options. Prior to exposure to the educational tool, 4.7% of women were already taking endocrine risk reduction, 38.7% were reducing alcohol intake, and 62.6% were exercising. Three months after initial use of BHD, 8.4% of women who considered endocrine risk reduction, 33% of women who considered alcohol reduction, and 46% of women who considered exercise pursued the risk-reducing activities. Unlike lifestyle interventions which are under the control of the patient, additional barriers at the level of the healthcare provider may be impeding the targeted use of endocrine risk reduction medications in women with elevated breast cancer risk.

Keywords: breast cancer; decision making; education aid; genetic counseling; personalized; risk reduction; validation study.

PubMed Disclaimer

Conflict of interest statement

COMPETING INTERESTS STATEMENT The authors declare that there are no competing interests.

Figures

Figure 1:
Figure 1:. Endocrine Risk Reduction Use and Considerations
Bar graph of endocrine risk reduction use and considerations of reducing alcohol in high and highest breast cancer risk participants. Data collected from immediate feedback survey. Note: N/A
Figure 2:
Figure 2:. Alcohol Reduction Use and Considerations
Bar graph of alcohol reduction and considerations of reducing alcohol in high and highest breast cancer risk participants. Data collected from immediate feedback survey. Note: N/A
Figure 3:
Figure 3:. Exercise Use and Considerations
Bar graph of exercise use and considerations of pursuing exercise in high and highest breast cancer risk participants. Data collected from immediate feedback survey. Note: N/A
Figure 4:
Figure 4:. Risk-Assessment Tool and Anxiety about Breast Cancer Risk (immediately after use)
Bar graph of anxiety and worry about breast cancer risk after use of tool (from feedback survey). Responses obtained through Likert Scale in immediate feedback survey and subset into high- and highest-risk groups. Note: N/A
Figure 5:
Figure 5:. Worry about Developing Breast Cancer (3 month follow up)
Bar graph of frequency of worry about breast cancer risk after use of tool. Responses obtained through Likert Scale in 3-month follow up survey and subset into high- and highest-risk groups. Note: N/A
See this image and copyright information in PMC

References

    1. Advani P, Moreno-Aspitia A. Current strategies for the prevention of breast cancer. Breast Cancer Targets Ther. 2014;6:59–71. doi:10.2147/BCTT.S39114 - DOI - PMC - PubMed
    1. Pruthi S, Heisey R, Bevers T. Personalized Assessment and Management of Women at Risk for Breast Cancer in North America. Womens Health. 2015;11(2):213–224. doi:10.2217/WHE.14.79 - DOI - PubMed
    1. Mocellin S, Goodwin A, Pasquali S. Risk-reducing medications for primary breast cancer: a network meta-analysis. Cochrane Database Syst Rev. 2019;4:CD012191. doi:10.1002/14651858.CD012191.pub2 - DOI - PMC - PubMed
    1. Cuzick J, Sestak I, Forbes JF, et al. Use of anastrozole for breast cancer prevention (IBIS-II): long-term results of a randomised controlled trial. The Lancet. 2020;395(10218):117–122. doi:10.1016/S0140-6736(19)32955-1 - DOI - PMC - PubMed
    1. Land SR, Wickerham DL, Costantino JP, et al. Patient-Reported Symptoms and Quality of Life During Treatment With Tamoxifen or Raloxifene for Breast Cancer PreventionThe NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 Trial. JAMA. 2006;295(23):2742–2751. doi:10.1001/jama.295.23.joc60075 - DOI - PubMed

Publication types

LinkOut - more resources